BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scagliola A, Miluzio A, Ventura G, Oliveto S, Cordiglieri C, Manfrini N, Cirino D, Ricciardi S, Valenti L, Baselli G, D'Ambrosio R, Maggioni M, Brina D, Bresciani A, Biffo S. Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. Nat Commun 2021;12:4878. [PMID: 34385447 DOI: 10.1038/s41467-021-25195-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Scagliola A, Miluzio A, Mori G, Ricciardi S, Oliveto S, Manfrini N, Biffo S. Inhibition of eIF6 Activity Reduces Hepatocellular Carcinoma Growth: An In Vivo and In Vitro Study. IJMS 2022;23:7720. [DOI: 10.3390/ijms23147720] [Reference Citation Analysis]
2 Gao Y, Yuan L, Zeng J, Li F, Li X, Tan F, Liu X, Wan H, Kui X, Liu X, Ke C, Pei Z. eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03503-7] [Reference Citation Analysis]
3 Soares NC, Ali A, Srinivasulu V, Sharaf BM, Giddey AD, Okendo J, Al-Hroub HM, Semreen MH, Hamad M, Al-Tel TH. Unveiling the mechanism of action of nature-inspired anti-cancer compounds using a multi-omics approach. J Proteomics 2022;265:104660. [PMID: 35728772 DOI: 10.1016/j.jprot.2022.104660] [Reference Citation Analysis]
4 Zhang F, Waheed S, Armato U, Wu J, Zhang C, Li Z. eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma. Front Oncol 2022;12:848346. [DOI: 10.3389/fonc.2022.848346] [Reference Citation Analysis]
5 Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting. EMBO J 2022;:e109823. [PMID: 35315941 DOI: 10.15252/embj.2021109823] [Reference Citation Analysis]
6 AlSudais H, Rajgara R, Saleh A, Wiper-Bergeron N. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia. J Cachexia Sarcopenia Muscle 2022;13:743-57. [PMID: 35014202 DOI: 10.1002/jcsm.12909] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Muñoz-ayala A, Chimal-vega B, García-gonzález V. Translation initiation and its relationship with metabolic mechanisms in cancer development, progression and chemoresistance. Disorders of Protein Synthesis 2022. [DOI: 10.1016/bs.apcsb.2022.05.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]